ELI LILLY AND COMPANY Dividends Payable, Current
ELI LILLY AND COMPANY (LLY) had Dividends Payable, Current of $1.35 billion as of 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:DividendsPayableCurrent · last filed 2025-08-07
- 2025-06-30: Dividends Payable, Current $1.35B.
- 2025-03-31: Dividends Payable, Current $0.00.
- 2024-12-31: Dividends Payable, Current $1.35B.
- 2024-09-30: Dividends Payable, Current $0.00.
| Period end | Dividends Payable, Current |
|---|---|
| 2025-06-30 | $1.35B 10-Q · filed 2025-08-07 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-01 |
| 2024-12-31 | $1.35B 10-Q · filed 2025-08-07 |
| 2024-09-30 | $0.00 10-Q · filed 2024-10-30 |
| 2024-06-30 | $1.17B 10-Q · filed 2024-08-08 |
| 2024-03-31 | $0.00 10-Q · filed 2024-04-30 |
| 2023-12-31 | $1.17B 10-K · filed 2025-02-19 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-02 |
| 2023-06-30 | $1.02B 10-Q · filed 2023-08-08 |
| 2023-03-31 | $0.00 10-Q · filed 2023-04-27 |
| 2022-12-31 | $1.02B 10-K · filed 2024-02-21 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-01 |
| 2022-06-30 | $882.20M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $0.00 10-Q · filed 2022-04-29 |
| 2021-12-31 | $885.50M 10-K · filed 2023-02-22 |
| 2021-09-30 | $0.00 10-Q · filed 2021-10-27 |
| 2021-06-30 | $770.80M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $0.00 10-Q · filed 2021-04-30 |
| 2020-12-31 | $770.60M 10-K · filed 2022-02-23 |
| 2020-09-30 | $0.00 10-Q · filed 2020-10-28 |
| 2020-06-30 | $0.00 10-Q · filed 2020-07-31 |
| 2020-03-31 | $0.00 10-Q · filed 2020-05-01 |
| 2019-12-31 | $671.50M 10-K · filed 2021-02-17 |
| 2019-09-30 | $0.00 10-Q · filed 2019-10-25 |
| 2019-06-30 | $593.90M 10-Q · filed 2019-08-02 |
| 2019-03-31 | $0.00 10-Q · filed 2019-05-02 |
| 2018-12-31 | $650.80M 10-K · filed 2020-02-19 |
| 2018-09-30 | $0.00 10-Q · filed 2018-11-06 |
| 2018-06-30 | $578.20M 10-Q · filed 2018-07-25 |
| 2018-03-31 | $0.00 10-Q · filed 2018-04-27 |
| 2017-12-31 | $590.60M 8-K · filed 2019-10-24 |
| 2017-09-30 | $0.00 10-Q · filed 2017-10-27 |
| 2017-06-30 | $547.50M 10-Q · filed 2017-07-28 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-01 |
| 2016-12-31 | $548.10M 10-K · filed 2018-02-20 |
| 2016-09-30 | $0.00 10-Q · filed 2016-10-28 |
| 2016-06-30 | $537.50M 10-Q · filed 2016-07-28 |
| 2016-03-31 | $0.00 10-Q · filed 2016-04-29 |
| 2015-12-31 | $539.00M 10-K · filed 2017-02-21 |
| 2015-09-30 | $0.00 10-Q · filed 2015-10-30 |
| 2015-06-30 | $529.20M 10-Q · filed 2015-07-30 |
| 2015-03-31 | $0.00 10-Q · filed 2015-04-30 |
| 2014-12-31 | $530.30M 10-K · filed 2016-02-19 |
| 2014-09-30 | $0.00 10-Q · filed 2014-10-29 |
| 2014-06-30 | $524.10M 10-Q · filed 2014-07-28 |
| 2014-03-31 | $0.00 10-Q · filed 2014-04-28 |
| 2013-12-31 | $523.50M 10-K · filed 2015-02-19 |
| 2013-09-30 | $0.00 10-Q · filed 2013-10-30 |
| 2013-06-30 | $527.00M 10-Q · filed 2013-07-26 |
| 2013-03-31 | $0.00 10-Q · filed 2013-04-26 |
| 2012-12-31 | $541.40M 10-K · filed 2014-02-19 |
| 2012-09-30 | $0.00 10-Q · filed 2012-10-26 |
| 2012-06-30 | $543.60M 10-Q · filed 2012-07-27 |
| 2012-03-31 | $0.00 10-Q · filed 2012-04-30 |
| 2011-12-31 | $542.30M 10-K · filed 2013-02-21 |
| 2011-09-30 | $0.00 10-Q · filed 2011-10-28 |
| 2011-06-30 | $542.30M 10-Q · filed 2011-07-29 |
| 2011-03-31 | $0.00 10-Q · filed 2011-04-29 |
| 2010-12-31 | $540.00M 10-K · filed 2012-02-24 |
| 2010-09-30 | $0.00 10-Q · filed 2010-10-29 |
| 2010-06-30 | $545.70M 10-Q/A · filed 2010-08-02 |
| 2010-03-31 | $0.00 10-Q · filed 2010-07-30 |
| 2009-12-31 | $538.00M 10-K · filed 2011-02-22 |
| 2009-09-30 | $0.00 10-Q · filed 2009-10-30 |
| 2009-06-30 | $538.00M 10-Q · filed 2009-07-31 |
| 2008-12-31 | $536.80M 10-K · filed 2010-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |